Lupin Builds Momentum As It Anticipates FDA Action On Spiriva Rival
Recent Boosts Also Include EIR For Nagpur Plant As Well As US Lurasidone Launch
Lupin has offered further specifics on expected FDA action for its proposed Spiriva generic, as the Indian firm reported a solid third financial quarter that saw an uptick in sales and profits, including turnover growth in the US.
